Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1229-1233. doi: 10.19723/j.issn.1671-167X.2022.06.029

Previous Articles     Next Articles

红霞 李1,雅馨 周1,亚飞 王2,鹏宇 王2,振彪 吴2,*()   

  • Received:2022-08-27 Online:2022-12-18 Published:2022-12-19
  • Contact: 振彪 吴 E-mail:wuzhenbiaoxjimmu@163.com
  • Supported by:
    National Key Research Development Program of China(201KTCL03_03)

RICH HTML

   

PDF (PC)

CLC Number: 

  • R593.2

Figure 1

Different changes of labial salivary glands in pSS patients A, normal pathology; B, lymphocyte infiltration (arrow) but no focus score (FS=0); C, non-specific chronic sialadenitis having lymphocyte infiltration (arrow); D, lymphocytic focuses (FS=6.3, arrow). FS, focus score; pSS, primary Sjögren's syndrome."

Table 1

Comparison of clinical parameters between positive-pSS and negative-pSS patients"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
Age/years, $\bar x \pm s$ 48.5±14.9 49.6±14.2 0.440 0.508
Gender (Males/Females), n 5/99 7/106 0.199 0.655
Duration/months, M(P25, P75) 12 (6, 45) 14 (6, 36) 0.802 0.423
Dry mouth 83 (79.8) 83 (73.4) 1.217 0.270
Dry eyes 62 (59.6) 59 (52.2) 1.203 0.273
Parotid swelling 11 (10.6) 15 (13.3) 0.374 0.541
Rampant caries 22 (21.2) 13 (11.5) 3.728 0.054
Arthralgia/Anthritis 16 (15.4) 28 (24.8) 2.957 0.086
Rash 20 (19.2) 22 (19.5) 0.002 0.965
Fever 5 (4.8) 8 (7.1) 0.496 0.481
Hematological involvement 34 (32.7) 34 (30.1) 0.171 0.680
  Leukocytopenia 29 (27.9) 22 (19.5) 2.133 0.144
  Thrombocytopenia 15 (14.4) 15 (13.3) 0.060 0.807
Interstitial pneumonia 10 (9.6) 10 (8.9) 0.038 0.846
Kidney involvement 7 (6.7) 5 (4.4) 0.551 0.458
Nerve involvement 5 (4.8) 9 (8.0) 0.894 0.344
WUSF rate≤0.1 mL/min 46/69 (66.7) 63/80 (78.8) 2.754 0.097
Schirmer test ≤ 5 mm/5 min 43/69 (62.3) 41/77 (53.2) 1.226 0.268
ESSDAI, $\bar x \pm s$ 6.7±5.4 5.7±4.4 3.486 0.063
  ESSDAI＜5 44 (42.3) 51 (45.1) 0.176 0.675
  5≤ESSDAI＜10 31 (29.8) 42 (37.2) 1.314 0.252
  ESSDAI≥10 29 (27.9) 20 (17.7) 3.214 0.073

Table 2

Comparison of immune indicators between positive-pSS and negative-pSS patients [n (%)]"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
ANA seropositive 101 (97.1) 111 (98.2) 0.009 0.925
  ANA titer = 1 ∶100 6 (5.8) 14 (12.4) 2.837 0.092
  ANA titer = 1 ∶320 9 (8.7) 20 (17.7) 3.723 0.054
  ANA titer = 1 ∶1 000 19 (18.3) 26 (23.0) 0.740 0.390
  ANA titer ≥ 1 ∶3 200 67 (64.4) 51 (45.1) 8.123 0.004
Anti-SSA 86 (82.7) 98 (86.7) 0.683 0.408
Anti-Ro-52 87 (83.7) 90 (79.6) 0.579 0.447
Anti-SSB 48 (46.2) 34 (30.1) 5.946 0.015
AMA-M2 8 (7.7) 15 (13.3) 1.781 0.182
Anti-CENP-B 8 (7.7) 10 (8.9) 0.095 0.757
Anti-RNP/Sm 11 (10.6) 12 (10.6) 0.000 0.992
Anti-dsDNA 0 1 (0.9)
Anti-CCP 1/40 (2.5) 2/43 (4.7) >0.999
IgG>1 600 mg/dL 71/96 (74.0) 60/99 (60.6) 3.941 0.047
IgA>450 mg/dL 18/96 (18.8) 13/99 (13.1) 1.151 0.283
IgM>270 mg/dL 9/96 (9.4) 7/99 (7.1) 0.344 0.558
C3 < 80 mg/dL 43/96 (44.8) 37/97 (38.1) 0.878 0.349
C4 < 16 mg/dL 36/96 (37.5) 33/97 (34.0) 0.254 0.614
RF seropositive 70/96 (72.9) 56/97 (57.7) 4.909 0.027
ESR>20 mm/h 48/83 (57.8) 31/82 (37.8) 6.629 0.010
CRP>0.8 mg/dL 9/94 (9.6) 5/97 (5.2) 1.373 0.241

Table 3

Analysis of variables associated with positive pathology in pSS patients"

Variables OR (95%CI) P value
Rampant caries 1.608 (0.723-3.576) 0.245
ANA titer ≥ 1 ∶3 200 1.592 (0.838-3.025) 0.155
Anti-SSB positive 1.190 (0.616-2.299) 0.604
ESR>20 mm/h 2.239 (0.657-2.337) 0.508
IgG>1 600 mg/dL 1.635 (0.813-3.290) 0.168
RF seropositive 0.875 (0.448-1.710) 0.696
ESSDAI
  ESSDAI < 5 Reference
  5≤ESSDAI < 10 0.711 (0.357-1.419) 0.334
  ESSDAI≥10 1.554 (0.723-3.340) 0.259
1 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59 (4): 269- 270.
doi: 10.3760/cma.j.cn112138-20200113-00021
2 Mariette X , Criswell LA . Primary Sjögren' s syndrome[J]. N Engl J Med, 2018, 378 (10): 931- 939.
doi: 10.1056/NEJMcp1702514
3 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren' s syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 76 (1): 9- 16.
doi: 10.1136/annrheumdis-2016-210571
4 Seror R , Ravaud P , Bowman SJ , et al. EULAR Sjögren' s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2010, 69 (6): 1103- 1109.
doi: 10.1136/ard.2009.110619
5 Vitali C , Bombardieri S , Jonsson R , et al. Classification criteria for Sjögren' s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6): 554- 558.
doi: 10.1136/ard.61.6.554
6 Guellec D , Cornec D , Jousse-Joulin S , et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren' s syndrome: A systematic review[J]. Autoimmun Rev, 2013, 12 (3): 416- 420.
doi: 10.1016/j.autrev.2012.08.001
7 Fisher BA , Jonsson R , Daniels T , et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2017, 76 (7): 1161- 1168.
doi: 10.1136/annrheumdis-2016-210448
8 Retamozo S , Acar-Denizli N , Rasmussen A , et al. Systemic manifestations of primary Sjögren' s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients[J]. Clin Exp Rheumatol, 2019, 37 (3/Suppl 118): 97- 106.
9 Luppi F , Sebastiani M , Silva M , et al. Interstitial lung disease in Sjögren' s syndrome: A clinical review[J]. Clin Exp Rheumatol, 2020, 38 (4/Suppl 126): 291- 300.
10 Lin W , Xin Z , Ning X , et al. Clinical features and risk factors of Raynaud' s phenomenon in primary Sjögren' s syndrome[J]. Clin Rheumatol, 2021, 40 (10): 4081- 4087.
doi: 10.1007/s10067-021-05749-w
11 Sharma R , Chaudhari KS , Kurien BT , et al. Sjögren syndrome without focal lymphocytic infiltration of the salivary glands[J]. J Rheumatol, 2020, 47 (3): 394- 399.
doi: 10.3899/jrheum.181443
12 Park Y , Lee J , Koh JH , et al. Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren' s syndrome in a Korean population[J]. Clin Exp Rheumatol, 2020, 38 (4/ Suppl 126):): 158- 165.
13 Risselada AP , Kruize AA , Goldschmeding R , et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2014, 73 (8): 1537- 1540.
doi: 10.1136/annrheumdis-2013-204634
14 Kakugawa T , Sakamoto N , Ishimoto H , et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren' s syndrome[J]. Respir Med, 2018, 137, 95- 102.
doi: 10.1016/j.rmed.2018.02.023
15 Wu S , Tang X , Wu L , et al. Anti-Ro52 antibodies in clinical practice: A single-centre experience[J]. Int J Clin Pract, 2021, 75 (3): e13679.
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3] Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4] Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9] Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10] Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12] Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14] Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd